Aytu Biopharma vs Rockwell Medical
Rockwell Medical is the larger business, with $69.3m of revenue in fiscal 2025 against $57.6m for Aytu Biopharma (1.2 times as much). Aytu Biopharma grew faster (-13.3% against -31.8%). Rockwell Medical kept more of each dollar of sales as profit: a net margin of -7.7% against -24.8%.
| Latest fiscal year | Aytu BiopharmaAYTU, 2026 | Rockwell MedicalRMTI, 2025 |
|---|---|---|
| Revenue | $57.6m | $69.3m |
| Revenue growth | -13.3% | -31.8% |
| Net income | −$14.3m | −$5.3m |
| Operating margin | — | — |
| Net margin | -24.8% | -7.7% |
| Return on equity | -52.6% | -15.3% |
| Free cash flow | $3.3m | −$1.2m |
| Cash | $26.3m | $10.7m |
| Total debt | $17.0m | $8.8m |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 76 | 157 |
| Market value | $20.8m | $32.2m |
| Price vs our value range | — | Above our value range |
| Moat score | 27 (Weak) | 35 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 4 sales |